Beyond Symptom Relief: Physician Empathy Outperforms Clinical Severity in Predicting Quality of Life for Patients Undergoing Botulinum Toxin Therapy
Objective: To evaluate the impact of patient-perceived physician empathy on health-related quality of life (HRQoL), treatment satisfaction, and clinical outcomes in patients receiving Botulinum Neurotoxin…Long-term utilization of onabotulinumtoxinA for the treatment of cervical dystonia
Objective: To characterize real-world long-term utilization of onabotulinumtoxinA (onabotA) for cervical dystonia (CD) treatment by describing demographic characteristics, clinical features, and treatment patterns of patients…Digital acoustic biomarkers of botulinum toxin response in laryngeal dystonia: a longitudinal case report
Objective: To assess whether longitudinal acoustic analysis can objectively capture treatment response to botulinum toxin type a (BoNT-A) in laryngeal dystonia. Background: Objective longitudinal markers…Impact of a Structured Patient Education Module on Knowledge of Botulinum Toxin Therapy, Goal Attainment, and Treatment Satisfaction in Cervical Dystonia
Objective: To evaluate the impact of a structured patient education program on knowledge and goal attainment, measured by the structured Goal Attainment Scale (GAS), following…Treatment Patterns in Adults with Isolated Dystonia in the United States
Objective: To characterize real-world treatment patterns in adults with isolated dystonia in the United States. Background: Isolated dystonia is a rare, complex movement disorder characterized…Long‑term dose-effect patterns with incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in cervical dystonia: multicenter real‑world analysis
Objective: To characterize long‑term dose-effect patterns for incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in cervical dystonia (CD) using a unified dose-effect parameter (DEff) and to compare complex‑free…Rare Observations of Sustained Symptomatic Improvement with Botulinum Toxin Type A Injections in Facial and Cervical Dystonia: Case Series
Objective: To describe prolonged improvement in patients with involuntary facial and cervical movements after BTX-A therapy. Background: Botulinum toxin type A (BTX-A) treatment is considered…Phasic Hemidystonia Secondary to Cavernoma: A Case of Sustained Response to Botulinum Toxin
Objective: To report a rare case of lentiform nucleus cavernoma with phasic-predominant hemidystonia and sustained BoNT response. Background: Cerebral cavernomas rarely present with movement disorders.…Are All Toxins Created Equal? Real-world analysis of Abo-, Inco- and Ona- BoNT-A from prospective LIVEchart over 7 years
Objective: To compare dosing, duration of action, and patient-reported outcomes across inco-, abo- and ona- BoNT (botulinum toxin) in cervical dystonia (CD), hemifacial spasm (HFS),…Predictors of Secondary Non-Response to Botulinum Neurotoxin Type-A in Cervical Dystonia: A Multi-Center Egyptian Study
Objective: To investigate clinical and treatment predictors of SNR in Egyptian CD patients receiving BoNT-A therapy. Background: Secondary non-response (SNR) to botulinum neurotoxin type-A (BoNT-A)…
- 1
- 2
- 3
- …
- 23
- Next Page »